Gilead Sciences | GILD - Selling And Administration Expenses


Gilead Sciences reported $1.52B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.43B 496M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
J&J USD 6.42B 381M Jun/2026
Merck USD 2.89B 219M Jun/2026
Moderna USD 216M 43M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 307M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
United Therapeutics USD 206.7M 50.1M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026